Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

receivable from Sanofi98,78199,913Deferred tax assets 300,951340,156Property, plant, and equipment, net392,378379,940Other assets117,22079,763Total assets$

2,275,998$

2,080,490LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable, accrued expenses, and other liabilities$

154,199$

118,604Deferred revenue252,703259,173Facility lease obligations160,480160,810Convertible senior notes302,268296,518Stockholders' equity1,406,3481,245,385Total liabilities and stockholders' equity$

2,275,998$

2,080,490 

TABLE 2REGENERON PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)(In thousands, except per share data)Three months endedMarch 31,20132012Revenues:Net product sales$

318,740$

127,931Sanofi collaboration revenue99,27385,005Bayer HealthCare collaboration revenue14,90712,483Technology licensing5,8935,893Other revenue851477439,664231,789Expenses:Research and development180,299138,862Selling, general, and administrative77,26058,428Cost of goods sold29,05512,298286,614209,588Income from operations153,05022,201Other income (expense):Investment income456610Interest expense(11,675)(11,160)(11,219)(10,550)Income before income taxes141,83111,651Income tax expense(42,957)Net income$

98,874$

11,651Net income per share - basic$

1.02$

0.12Net income per share - diluted$

0.90$

0.11Weighted average shares outstanding - basic96,87893,446Weighted average shares outstanding - diluted109,369107,734 TABLE 3REGENERON PHARMACEUTICALS, INC.RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME (Unaudited)(In thousands, except per share data)Three months endedMarch 31,20132012GAAP net income$

98,874$

11,651Adjustments:R&D: Non-cash share-based compensation expense 26,76110,556SG&A: Non-cash share-based compensation expense25,78712,578COGS: Non-cash share-based compensation expens
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... India Solid Waste Management Vehicles Market Forecast ... In India ... responsible for complete handling and regulation of solid ... 135,000 MT solid waste is generated daily in ...
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... Innovation, Inc. (BHI), a regional private-public partnership focusing ... early-stage funding in Central Maryland, announced today the appointment ... at Qiagen , to its Board of ... to our board," said Scott Carmer, BioHealth Innovation, Inc. ...
... by Kathleen Eggleson, a research scientist in the Center ... of Notre Dame, provides an example of a nanotechnology-related ... The world of nanotechnology, which involves science and ... But like most new advances, the application of that ...
... On April 19, 2012, GeneLink,s common stock began trading ... this will be temporary as it is due to the ... for the period ended December 31, 2011.  The Company anticipates ... on Form 10K for the period ended December 31, 2011 ...
Cached Biology Technology:BioHealth Innovation, Inc. Appoints Qiagen's Douglas Liu to Board of Directors 2Notre Dame paper examines nanotechnology-related safety and ethics problem 2Notre Dame paper examines nanotechnology-related safety and ethics problem 3GeneLink Anticipates Completion of Audit 2
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... the same DNA sequence their genetic information. How ... in the different parts of the body are so ... master plan, an additional regulatory layer exists that determines ... This mechanism involves modifications of genome-bound histone proteins or ... It acts on top of the genetic information and ...
(Date:9/2/2014)... the September issue of The FASEB Journal ... to diagnose the leading cause of blindness in ... occurred. This advance involves quantifying the early molecular ... retinal vessels. Using new probes developed by scientists, ... development of diabetic retinopathy. , "My goal is ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... Scientists have discovered that a stem cell factor overexpressed ... brain injury promotes tumor survival by inducing angiogenesis. The ... Cell, examines the interaction between tumor cells and surrounding ... more effective therapeutics for one of the most lethal ...
... In an unexpected discovery, scientists at Jefferson Medical College ... virus protein can turn a "safe" virus extremely deadly. ... vaccine they previously created against rabies in wildlife, making ... a molecular mechanism involved in making the rabies virus ...
... disease in the brain of the fruit fly, researchers ... proteins previously associated with cancer. , The findings are ... Brigham and Women's Hospital, Harvard Medical School, and the ... not divide. It is therefore perplexing that in Alzheimer's ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Jefferson researchers building a better rabies vaccine 2
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: